文献速递胸部肿瘤支持与姑息治疗

2006年以来肺癌患者倡导的进展与新挑战

Lung Cancer Patient Advocacy Progress and New Challenges Since 2006.
PubMed 文献 · J Thorac Oncol · 2026-01-01

本文回顾了2006年以来肺癌患者倡导的发展历程:靶向治疗、免疫治疗、分子诊断、筛查及手术放疗技术的进步改变了患者体验,倡导组织在推动科学成果转化为公平、以患者为中心的照护中发挥关键作用。文章还讨论了倡导组织在减少污名、影响政策、参与研究全流程方面的作用,以及中低收入国家倡导工作的发展与挑战。

要点

  • 倡导组织已从早期基层社群发展为国家和国际联盟,参与研究设计、方案审查和结果传播。
  • 倡导者推动控烟措施和反污名工作,但污名仍阻碍患者获得照护和参与研究。
  • 中低收入国家倡导工作仍在发展,2025年阿克拉首届泛非肺癌大会是重要里程碑。

核心结论

  • 患者倡导是肺癌预防、筛查、治疗和支持性照护可及性进步的重要驱动力。
  • 倡导应正式嵌入试验设计、临床指南制定、研究项目实施和结果传播,以促进公平可及的创新照护。

研究设计与样本

  • 本文为综述/观点文章,未报告系统检索范围或样本量。

主要发现

  • 过去二十年靶向治疗、免疫治疗、分子诊断、筛查及手术放疗技术的变革性进展显著改变了肺癌患者体验。
  • 倡导组织已扩展、专业化并形成国家和国际联盟,放大集体声音并协调跨国政策努力。
  • 社交媒体使患者广泛连接,生物标志物驱动的社群出现,倡导者与研究者合作加深。
  • 欧洲许多肺癌患者倡导组织由患者及家属发起,常始于基层或在线社群,后扩展为全国或欧洲网络,如Lung Cancer Europe、ALK Positive Europe和Women Against Lung Cancer in Europe。
  • 2025年阿克拉首届泛非肺癌大会将早期检测、照护者支持、政策改革和社区教育列为优先事项。

临床怎么用

  • 倡导组织可作为研究全流程的必要合作伙伴,参与研究概念形成、方案审查、患者材料共同设计和结果传播。
  • 临床与研究团队应将患者倡导正式纳入试验设计、指南制定和研究项目实施,以促进公平可及的照护。

局限性

  • 本文为综述/观点文章,未报告系统检索策略、纳入标准或定量数据。
  • 文中指出污名仍阻碍照护可及性和研究参与,中低收入国家倡导工作仍在发展中。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

In the past, people with lung cancer received less public recognition and fewer organized support systems, compared with other cancer communities (such as pediatric or breast cancer). In the 1990s, limited benefit from systemic therapies discouraged support networks and advocacy. However, in the past two decades, transformative advances in targeted therapies, immunotherapy, molecular diagnostics, screening programs, and surgical and radiotherapy techniques have dramatically changed the patient experience. Advocacy organizations have played a crucial role in ensuring that these scientific gains translate into meaningful, equitable, patient-centered care. This article highlights lung cancer patient advocacy as an essential driver of progress in access to prevention, screening, treatment, and supportive care. Advocates have challenged stigma, underfunding, and neglect. Over time, organizations have expanded, professionalized, and formed national and international coalitions, amplifying their collective voice and coordinating policy efforts across countries. Beginning in the late 1990s, early organizations laid the groundwork for private research funding and public awareness. The 2010s marked a turning point, with social media enabling widespread patient connection, biomarker-driven communities emerging, and deepening collaboration between advocates and researchers. Today, advocacy groups serve as essential partners across the research continuum, shaping study concepts, reviewing protocols, co-designing patient-facing materials, and enhancing the dissemination of results. For example, across Europe, many lung patient advocacy organizations have been initiated by patients and their families, often starting as grassroots or online communities, or social networks, and later expanding into national or European networks. Examples include Lung Cancer Europe, ALK Positive Europe, and Women Against Lung Cancer in Europe, illustrating a decentralized yet strongly patient-led advocacy model. Advocates have also influenced public policy and societal perceptions. Their efforts have strengthened tobacco control measures and advanced anti-stigma work that centers dignity, respect, and person-first language. Despite meaningful progress, stigma continues to impede access to care and participation in research. Advocacy organizations work to change public perception because people with lung cancer deserve the same care and respect as people with other forms of cancer. Globally, advocacy in low- and middle-income countries is still developing but is increasingly recognized as vital. A major milestone was the first Pan-African Lung Cancer Conference in Accra in 2025, where advocates prioritized early detection, caregiver support, policy reform, and community education, while acknowledging the need for long-term infrastructure development. As lung cancer care becomes more complex, patient advocacy remains indispensable in promoting equitable access, harmonizing policy across regions, accelerating innovation, and expanding survivorship support. To sustain progress, advocates should be formally embedded in trial design, clinical guideline development, implementation of research projects, and dissemination of research findings and support the health care ecosystem so innovations in research and care are accessible, timely, and equitable. The field is entering an "Impact Era," where success is measured not only by survival but by how well people live. Advocacy will continue to drive systems toward more patient-centered and equitable lung cancer care locally, nationally, and globally.

来源:J Thorac Oncol,查看原文。版权归原作者所有。

引用

  1. Pujol JL, Roy UB, Feldman J, et al. Lung Cancer Patient Advocacy Progress and New Challenges Since 2006. J Thorac Oncol. 2026. PMID: 42552032. doi:10.1016/j.jtho.2026.103892

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。